Mode
Text Size
Log in / Sign up

Hepatitis

Subtypes of Hepatitis

Hepatitis B 32 Hepatitis C 21 Hepatitis A 8 Autoimmune hepatitis 4 Hepatitis E 3 Rift Valley Fever 2 Viral hepatitis 2 Acute Hepatitis of Unknown Etiology in Children 1 Acute Hepatitis of Unspecified Etiology 1 Acute Nonviral Hepatitis 1 Alcohol-Associated Hepatitis 1 Cholestatic hepatitis 1 Chronic Hepatitis Delta Virus Infection 1

75 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hepatitis

17 trials tracked for Hepatitis: 5 in phase 3 or 4 and 1 with published results. The most-cited published study has 4 citations.

17Trials tracked
5Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 4 Phase 2 8 Phase 1 1 Other / NA 3
  1. Phase 4 Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines Completed · 4 cited
  2. Phase 3 Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C Completed
  3. Phase 3 PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) Completed
  4. Phase 3 An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients Completed
  5. Phase 3 Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis Completed
  6. Phase 2 Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects Completed
Show 11 more trials
  1. Phase 2 A Network & Dyad HIV Prevention Intervention for IDU's - 1 Completed
  2. Phase 2 Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection Completed
  3. Phase 2 A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal. Completed
  4. Phase 2 Treating Nonalcoholic Steatohepatitis (NASH) With Metformin Completed
  5. Phase 2 Treating Nonalcoholic Steatohepatitis With Pioglitazone Completed
  6. Phase 2 HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) Completed
  7. Phase 2 Lamivudine and Adefovir to Treat Chronic Hepatitis B Completed
  8. Phase 1 Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Completed
  9. N/A The Health Access and Recovery Peer Program Completed
  10. N/A Twinrix Pregnancy Registry Completed
  11. N/A Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hepatitis: what the trials found

Established evidence includes the use of Telbivudine for managing liver condition, with data showing specific counts of patients experiencing improvement, stabilization, or worsening in Child-Turcotte-Pugh (CTP) scores at weeks 52 and 104 5, as well as improvements in modified CTP scores 5. PegIntron (peginterferon alfa-2b; SCH 54031) has also been evaluated in a large-scale study 6.

Regarding hepatitis C virus (HCV) treatment, Algeron demonstrated specific rates for Early Virological Response (EVR), Rapid Virological Response (RVR), and Sustained Virological Response (SVR) across multiple trial arms [3, 4]. Additionally, Fendrix suspension is established as an intervention for Hepatitis B 2.

Recent results — preliminary, needs further review

  • Isoniazid was evaluated for TB treatment completion rates in a prison setting, showing results of 114 and 127 (p=0.08) 1.

For the clinician treating this condition

  • Telbivudine is associated with measurable changes in CTP scores at 52 and 104 weeks 5.
  • Fendrix is established for Hepatitis B prophylaxis 2.
  • Algeron shows consistent results across EVR, RVR, and SVR metrics [3, 4].

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Hepatitis

Is there an increase in pediatric hepatitis of unknown cause in the US?

Recent reports indicate there was no increase in pediatric hepatitis of unknown cause or adenovirus trends in US children compared to pre-pandemic levels.

Full answer →
What causes severe hepatitis in children with adenovirus infection in Alabama?

Severe hepatitis in children with adenovirus in Alabama is linked to specific enteric serotypes like 41, which cause intense liver inflammation and immune reactions, though the virus's exact role as the sole cause remains unclear.

Full answer →
Has the US analysis found a common cause for acute hepatitis in kids?

US analysis has not found a single common cause for acute hepatitis in children, though some cases are linked to adenovirus while others remain unknown.

Full answer →
Do adenovirus stool testing results show higher levels than pre-pandemic times?

No, adenovirus stool testing results have not shown higher levels than pre-pandemic times, according to US surveillance data.

Full answer →
Is there an increase in pediatric hepatitis of unknown cause in the US?

No, US surveillance data through 2022 found no increase in pediatric hepatitis of unknown cause or adenovirus trends compared to pre-pandemic levels.

Full answer →
Can adenovirus infection cause severe hepatitis in children?

Adenovirus infection has been found in children with severe acute hepatitis, but its exact role as the cause is still unclear to doctors.

Full answer →
See all 6 questions about Hepatitis →